Choksi Laboratories shareholders approved the company’s audited financial statements for FY26 and re-appointed key directors at its 33rd Annual General Meeting held on September 18, 2026. The resolutions passed with overwhelming support, with promoter group voting reaching 100% in favor across all items.

The meeting was conducted via video conference from the company’s registered office in Indore, Madhya Pradesh. Sunil Choksi, Chairman and Managing Director, declared the meeting open after confirming quorum. The session commenced at 12:30 pm and concluded at 12:42 pm.

Voting Results

Shareholders holding shares as of September 11, 2026, were eligible to vote. A total of 3,921 shareholders were on record. Of these, 38 shareholders attended the meeting through video conferencing (four from the promoter group and 34 from the public).

Remote e-voting was facilitated through Central Depository Services (India) Limited between September 15 and September 17, 2026. Ms. Surabhi Agrawal served as the scrutinizer for the process.

Resolution-wise Breakdown

Promoter and promoter group holdings stood at 2,192,754 shares. They cast all their votes electronically, resulting in a 100% approval rate for every resolution. Public non-institutional shareholders held 4,772,509 shares, polling 12,081 votes via remote e-voting.

Key Resolutions Passed

Three primary resolutions were tabled during the session:

• Adoption of Audited Financial Statements: Shareholders approved the balance sheet and profit and loss account for the fiscal year ended March 31, 2026, along with reports from the Board of Directors and Auditors.
• Re-appointment of Sunil Choksi: Mr. Choksi retires by rotation under Section 152(6) of the Companies Act, 2013. Being eligible, he offered himself for re-appointment as Managing Director.
• Re-appointment of Himika Choksi: Ms. Choksi was approved for re-appointment as a Whole-Time Director. This required a special resolution.

All directors, key managerial personnel, and auditors attended the proceedings virtually. The scrutinizer’s report confirmed that the voting process complied with Section 108 of the Companies Act, 2013, and Rule 20 of the Companies (Management and Administration) Rules, 2014.

Choksi Laboratories has approved the preferential allotment of convertible equity warrants to its promoters, raising up to ₹6.19 crore. The Board of Directors finalized the proposal during a meeting held on September 19, 2026, and scheduled an Extra-Ordinary General Meeting (EGM) for shareholder approval on October 17, 2026.

The company will issue up to 3,50,000 warrants to three promoter group entities: Mr. Sunil Choksi, Ms. Himika Choksi, and Mrs. Stela Choksi. Each warrant is priced at ₹177 and is fully convertible into one equity share of face value ₹10. The pricing adheres to Regulation 165 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, based on the relevant date of September 17, 2026.

Allotment Details

The proceeds from the issue will be utilized for general corporate purposes, subject to shareholder approval. The payment structure requires 25% of the warrant issue price to be paid at subscription, with the remaining 75% payable upon exercise.

The post-issue shareholding pattern assumes full conversion of all warrants. Mr. Sunil Choksi’s stake is set to increase from 7.51% to 9.89%, while Ms. Himika Choksi’s holding will rise significantly from 0.01% to 1.38%.

Regulatory Compliance and Timeline

The approval was disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The warrants have a tenure of 18 months from the date of allotment. Unexercised warrants will lapse, and the amounts paid by holders will be forfeited by the company.

CS Surabhi Agrawal has been appointed as the scrutinizer for the e-voting process during the EGM, which will be conducted via Video Conferencing or Other Audio-Visual Means. The Board meeting commenced at 11:30 am and concluded at 3:50 pm at the company’s registered office in Indore.